Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Glutamate ionotropic receptor kainate type subunit 3 (GluK3) is a protein encoded by the GRIK3 gene that functions as a subunit of the ionotropic kainate-type glutamate receptor [1, 2]. It forms ligand-gated ion channels that are permeable to cations, primarily sodium and potassium, and sometimes calcium, mediating fast excitatory neurotransmission in the central nervous system [3, 11]. GluK3 is uniquely localized at both presynaptic and postsynaptic membranes, where it plays a critical role in modulating neurotransmitter release and regulating synaptic plasticity, particularly at hippocampal mossy fiber synapses [8, 13]. It is characterized by a relatively low affinity for glutamate and rapid desensitization compared to other kainate receptor subunits [12, 16]. Dysregulation or genetic variations in GluK3 have been linked to several neuropsychiatric and neurodevelopmental conditions, including schizophrenia, epilepsy, and developmental delay [2, 4, 5]. Additionally, aberrant expression of GluK3 has been observed in certain cancers, such as breast and colorectal cancer, where it may promote tumor progression [4, 6]. Pharmacological research has identified several agonists and antagonists, including selective compounds like Compound 28, which are being explored for their therapeutic potential in treating CNS disorders [8, 10].
Agonism, competitive antagonism, and allosteric modulation of the ionotropic kainate receptor channel, which regulates cation influx and membrane depolarization [3, 8, 11, 17].
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Glutamate ionotropic receptor kainate type subunit 3 (GluK3) (GluK3).